title: [Patient receiving peritoneal dialysis after treatment of ovarian cancer].
abstract: Peritoneal dialysis is one of the three available options for renal replacement therapy. This method of treatment of end-stage renal disease gives patients relatively high sense of independence and control over their disease, especially in comparison with hemodialysis, and therefore is often preferable method for young individuals wishing to lead an active lifestyle. We present a case of 22 year old female patient with stage 5 of chronic kidney disease, which is a consequence of multi-agent chemotherapy for endo-dermal sinus tumor of the right ovary (diagnosed at the age of 13). Particularly important in the context of treating our patient with peritoneal dialysis is the fact of confirmed metastases into the peritoneum, which was the reason for the use of chemotherapy reserved for high-risk patients (ifosfamide + etoposide + cisplatin). The selected program of chemotherapy provided effective eradication of cancer, but a side effect of treatment was renal tubular damage. In the period from 03.2006 to 05.2007 our patient required hemodialysis (with gradually reduce dose of dialysis), at a later time to 12.2011 patient did not require renal replacement therapy (stable renal function were observed at the stage 4 of chronic kidney disease), but in 12.2011 resumption of dialysis was necessary and the patient, in accordance with her selection, is receiving peritoneal dialysis. Qualification of our patient for treatment with peritoneal dialysis was associated with reasonable concern about the ability to provide acceptable adequacy of dialysis. Apprehensions proved to be unfounded, the clinical observation of the patient presents proper ratios of dialysis adequacy. Our patient was also qualified for renal transplantation.
authors.forename: Piotr
authors.initials: P
authors.lastname: Jaśkowski
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Krzanowska
authors.forename: Przemysław
authors.initials: P
authors.lastname: Miarka
authors.forename: Marcin
authors.initials: M
authors.lastname: Krzanowski
authors.forename: Wiadysław
authors.initials: W
authors.lastname: Sułowicz
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000008:administration & dosage; D007684:Kidney Tubules / Q000187:drug effects; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D010530:Peritoneal Dialysis; D010534:Peritoneal Neoplasms / Q000556:secondary; D051436:Renal Insufficiency, Chronic / Q000139:chemically induced* / Q000628:therapy*
chemical_list: D005047:Etoposide; D002945:Cisplatin; D007069:Ifosfamide